BerkovichR.Treatment of acute relapses in multiple sclerosis. Neurotherapeutics2013; 10(1): 97–105.
2.
BowenJDQianP. Oral rather than intravenous corticosteroids should be used to treat MS relapses – No. Mult Scler2017; 23(8): 1058–1060.
3.
BeckRWClearlyPAAndersonMMJr. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med1992; 326(9): 581–588.
4.
Le PageEEdanG. Oral rather than intravenous corticosteroids should be used to treat MS relapses – Yes. Mult Scler2017; 23(8): 1056–1058.
5.
Le PageEVeillardDLaplaudD. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): A randomised, controlled, double-blind, non-inferiority trial. Lancet2015; 386: 974–981.
6.
GrimaDTTorranceGWFrancisG. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler2000; 6(2): 91–98.
7.
KarampampaKGustavssonAMiltenburgerC. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: The costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol2012; 19(1): e11–e25.
8.
PatwardhanMBMatcharDBSamsaGP. Cost of multiple sclerosis by level of disability: A review of literature. Mult Scler2005; 11(2): 232–239.
9.
O’BrienJAWardAJPatrickAR. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res2003; 3: 17.
10.
AlmonRRDuBoisDCBrandenburgEH. Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis. J Pharmacokinet Pharmacodyn2002; 29: 103–129.
11.
DeferGLBarreJLedudalP. Methylprednisolone infusion during acute exacerbation of MS: Plasma and CSF concentrations. Eur Neurol1995; 35: 143–148.
12.
AntalEJWrightCEIIIGillespieWR. Influence of route of administration on the pharmacokinetics of methylprednisolone. J Pharmacokinet Biopharm1983; 11: 56–76.
13.
VolpeNJ.The optic neuritis treatment trial: A definitive answer and profound impact with unexpected results. Arch Ophthalmol2008; 126(7): 996–999.
14.
The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up. Arch Neurol2008; 65(6): 727–732.
15.
BurtonJMO’ConnorPWHoholM. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev2012; 12: CD006921.
16.
MartinelliVRoccaMAAnnovazziP. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology2009; 73(2): 1842–1848.
17.
Ramo-TelloCGrau-LopezLTintoreM. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler2014; 20: 717–725.
